Abstract
Dual antiplatelet therapy (DAPT) combined of aspirin and P2Y12 receptor inhibitors is the mainstay of treatment after acute coronary syndrome (ACS), but there are some problems remained to be explored, such as the duration of DAPT and choice of P2Y12 receptor inhibitors. This protocol is to evaluate the clinical benefit of pharmacogenomics (PGx)-based strategy of DAPT for ACS patients through a real-world study. A total of 6037 ACS patients are expected to be included in the study, with 3185 patients assigned to the PGx group and 3185 patients to the standard treatment group. The primary endpoint is major adverse cardiovascular events (MACE). The secondary endpoint is main efficacy indicators and composite outcome of stent thrombosis. The safety endpoint is major bleeding (BARC 2, 3, 4, 5) and fatal bleeding. We expect lower incidence of MACE and bleeding events in patients with genotype-guided treatment, compared to treatment as usual. Consequently, this protocol is expected to identify a genotype-based strategy of precise medication of antiplatelet therapy.